The central aim of synthetic biology is to create and exploit biological processes that do not occur naturally. In many cases this will involve one or more steps in genetic engineering to create an organism that so far has not been found in nature. In contrast, systems biology aims to describe biological processes in their entirety, be it the complete genome of an organism, community or ecosystem, or the processes occurring in such biological systems. Systems biology adopts a top-down approach; in contrast, synthetic biology requires a bottom-up approach: first a problem is identified; data from many possible sources, including systems biology, can then be searched for possible solutions.
The current thematic issue explores some of the applications of synthetic biology. While systems biology strives to provide a complete description of what is available naturally, synthetic biology exploits this information to design solutions to a specific problem. The study by Quirino and Beier nicely illustrates this principle. It is just one of the contributions to this thematic issue that originated from poster or lecture presentations during the 5th FEMS Congress of Microbiology held in Leipzig in July 2013. Our scope was limited by an unexpected paucity of contributions in Leipzig exploring exciting contributions being made across Europe, for example, to the use of synthetic biology to generate replacements for naturally synthesized antibiotics. Also in strikingly low abundance were presentations on small RNAs: their global occurrence; their roles in the regulation of gene expression; and their potential for medical exploitation as antisense RNA. We are therefore pleased to include the article by Philipps et al. 'Expression of Porphyromonas gingivalis small RNA in response to hemin availability identified using microarray and RNA-seq analysis'. Genetic engineering is undoubtedly one of the cornerstones of synthetic biology, not least for the production of recombinant proteins in heterologous hosts. While yeast and Escherichia coli strains have dominated the recombinant protein production literature, there is also keen interest in exploiting the secretion potential of Gram-positive bacteria. Jørgensen, Vrang and Madsen present a classic example of how problems of growth inhibition due to excessive lactate accumulation by Lactococcus lactis can be alleviated by combining a novel cloning system with physical removal of lactate from the culture by electrodialysis. A proof-of-principle experiment is described in which a nuclease from Staphylococcus aureus was accumulated in the heterologous host to a concentration of 2.5 g L
À1
.
Despite the paucity of presentations in Leipzig in some important areas of microbiology, an attempt has been made in this volume to illustrate not only the breadth of topics that currently fall under the synthetic or systems labels, but also to explore how they might be related. This introduction also alerts our broader readership to the merits and drawbacks associated with the inevitable jargon that each new subdiscipline generates.
What are the limits of 'synthetic biology'?
A panel convened by the European Commission concluded that current genetic engineering regulations were sufficient to regulate synthetic biology research. The contribution by Bohlke and Budisa summarizing current progress in how the genetic code can be expanded to incorporate artificial amino acids into proteins beautifully illustrates such an approach. Also falling within this traditional category is the recombination of genes from related biosynthetic pathways but from different organisms to create hybrid organisms that generate unnatural products. The review by Cummings, Breitling and Takano entitled 'Steps towards the synthetic biology of polyketide biosynthesis' describes factors that limit current efforts to develop synthetic polyketide antibiotics. If successful, these synthetic antibiotics might be able to replace naturally synthesized antibiotics yet avoid problems of antibiotic resistance. However, major challenges remain to be resolved. This is because polyketide secondary metabolites are products of biosynthetic pathways that depend upon complexes of multiple proteins with multiple domains functioning as an integrated unit. Until the mechanisms of such protein complexes are better understood, it is na€ ıve to believe that modules from different organisms and different pathways can be recombined into functional units.
Is it true that all synthetic biology starts with genetic engineering to create an unnatural new organism? Such a definition would eliminate from synthetic biology, the chemical modification of products of natural biological processes; or the use of chemistry to solve a biological problem. The article by Chudobova et al. compares the effects of silver and selenium nanoparticles on growth and DNA integrity in S. aureus. The results suggest new lines of chemotherapy to protect against this opportunist pathogen. In a second nanoparticle study, 'Sensitivity of bacteria to diamond nanoparticles of various size differs in Gram-positive and Gram-negative cells' by Beranova and colleagues, the authors conclude that inhibitory effects of diamond nanoparticles might be due to the inhibition of nutrient transport. It is left to the reader to decide whether these two articles on the exploitation of nanoparticles meet the requirements of synthetic biological research. If the answer is no, one must also reject other mainstream aspects of synthetic biology, including the exploitation of proteoliposomes and styrene maleic acid lipid particles (SMALPs) in microbiological research. Proteoliposomes have long been used to study bioenergetic and electron transfer processes in artificial biological membranes (Bannerjee & Datta, 1983) . SMALPs are nanoparticles developed by the Dafforn group to purify and characterize highly insoluble membrane proteins such as chemoreceptors from mammalian and microbial membranes (Knowles et al., 2009 ). Advantages of SMALPs over traditional ways to solubilize proteins such as detergents include enhanced stability, activity and spectral quality of the protein membranes. In summary, synthetic biology is not restricted to the exploitation of genetic engineering research.
Interplay between systems and synthetic biology
Several articles in this volume describe mainstream systems biological approaches to specific problems. One example is the minireview by R€ uter and Hardwidge 'Drugs from Bugs: bacterial effector proteins as promising biological (immune-) therapeutics.' It lies at the systems biology end of the spectrum, but summarizes research with obvious scope for applications by synthetic biologists. Similar opportunities are highlighted in the article 'Novel Amycolatopsis balhimycina biochemical abilities unveiled by proteomics' by Alduina et al. One might argue that applications in synthetic microbiology are less likely from the study of Romero, Marino and Pieckenstain entitled 'Metagenomic analysis of leaf-endophytic and rhizospheric bacterial communities of tomato (Solanum lycopersicum L.) plants'. Readers are challenged to confound this prediction! A senior colleague sitting at a conference between two systems biologists was dismayed by the following comment on the lecture being presented. 'These data do not agree with our mathematical model: therefore the experimental data must be wrong'! Two contributions to this volume illustrate current limitations of mathematical modelling or bioinformatic analysis of data generated by a systems biological approach. First, the article by Golec et al. entitled 'Bacteriophage T4 can produce progeny virions in an extremely slowly growing E. coli host' includes an illustration of the frequently encountered problem that experimental data are often at variance with the mathematical model that they were designed to validate. Conversely, the article by Beier et al. entitled 'Selection of a DNA aptamer against norovirus capsid protein VP1' illustrates how a mathematical model can be improved if an open-minded approach is taken to data analysis. This article could easily have been rejected from the volume on two grounds: first, it describes the enrichment and identification of an aptamer against a mammalian virus (a subject not within the remit of FEMS Letters); second, it includes intense mathematical data analysis. Nevertheless, it is included because the implications for exploitation of the methods developed in related fields of pathogenicity are so widespread.
Also included is a 'Commentary' that challenges the validity of relying only on sequencing the gene for 16S RNA as a basis for full metagenomic studies. This question proved to be unexpectedly provocative at another recent conference, and its significance is explored in the brief article by Esposito and Kirschberg. Readers are invited to respond to the many questions and controversies raised in any of the articles in this volume.
The emerging language of synthetic biology
Every scientific discipline evolves. Nowhere is this more obvious than in the evolution of biochemistry, which in the last 40 years has spawned molecular biology, molecular genetics, structural biology, molecular cell biology, metabolic engineering and more recently metabolomics amongst many others. This evolution is often accompanied by the creation of a new language that can hamper rather than enhance communication. The latest language to join the club is that of synthetic biology. It ranges from terminology that enhances communication by helping the nonspecialist understand underlying principles to jargon that verges on the ridiculous.
We will begin with some useful terms that are uncontroversial. Purification of novel proteins, for more than 30 years, has been facilitated by the addition of artificial 'tags' such as the immunogenic Myc and FLAG sequences, or the more commonly used histidine tags. The fusion of an insoluble target protein to a soluble one often aids accumulation, and hence purification, of the target component. The concept of decoupling is helpful to understand how to segregate required functions from biosynthetic pathways that require large proteins with multiple functional interacting domains. This generates references to interacting partners, and even to the concept of a scaffold on which new complexes might be assembled. Recombineering is a term used to describe the mixing of genetic components from different sources to create functions that apparently have yet to evolve naturally. As, by definition, synthetic biology is concerned with processes that so far have not been found naturally, do we need to refer to them as 'new-to-nature'?
While terms like synthetic switches, modularity, combinatorial biosynthesis, scaffolds, orthogonal pathways and decoupling are helpful and the concept of genetic engineering is well established, what is the advantage of adding extra terms such as 'tailoring' or the tautologous 'rational design'? Some synthetic biotechnologists advocate the introduction of standardisation into their procedures, presumably to facilitate process validation by regulatory authorities. This has led to the introduction of a plethora of engineering jargon into biology. Geneticists used to clone genes into vectors and express the gene in a microbial host. With the arrival of biochemical engineers onto the synthetic biology scene, this has now been translated into 'the engineering of biobricks from the toolbox by rational design for production in the chassis of the platform used for benchmarking.' It is for the reader to judge whether this has taken us from the sublime to the ridiculous.
